ERBB2 and breast cancer: Pamiparib (BGB-290) has been approved in China for the treatment of ovarian cancer, fallopian tube cancer and peritoneal cancer [242] and phase II studies are evaluating its efficacy as treatment for HER2− BC with BRCA mutation (NCT03575065) [243].